文献速递神经免疫神经肌肉病

伊奈利珠单抗治疗全身型重症肌无力急性加重与挽救治疗的III期试验预设分析

Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-01-01

MINT是一项III期随机安慰剂对照试验,纳入238例全身型重症肌无力患者,按方案进行激素减量。预设分析显示,伊奈利珠单抗较安慰剂降低急性加重风险:合并人群26周HR 0.41,AChR+亚组52周HR 0.39,MuSK+亚组26周HR 0.21。

要点

  • 伊奈利珠单抗降低全身型重症肌无力患者急性加重风险,包括挽救治疗使用。
  • AChR+亚组52周HR 0.39,MuSK+亚组26周HR 0.21,合并人群26周HR 0.41。
  • 获益见于按方案激素减量至≤5 mg/天的患者。

核心结论

  • 在MINT试验的预设分析中,伊奈利珠单抗降低接受方案规定激素减量的全身型重症肌无力患者的急性加重率,包括挽救治疗使用。

研究设计与样本

  • 筛查485例gMG患者,入组238例MG-ADL评分6-10的成人患者,随机1:1接受伊奈利珠单抗或安慰剂。
  • AChR+亚组随机对照期52周,MuSK+亚组26周,随后可选3年开放标签扩展。

主要发现

  • 合并人群26周急性加重风险HR 0.41(95%CI 0.24-0.70)。
  • AChR+亚组52周HR 0.39(95%CI 0.23-0.68)。
  • MuSK+亚组26周HR 0.21(95%CI 0.06-0.79)。

关键数值与推荐

  • 急性加重定义为肌无力危象、个体MG-ADL评分恶化或挽救治疗(静脉免疫球蛋白或血浆置换)使用。
  • 基线平均(SD)年龄47.5(15.3)岁,女性144例(61%),平均(SD)MG-ADL评分9.1(2.8)。

临床怎么用

  • 对于接受激素减量的AChR+或MuSK+全身型重症肌无力患者,伊奈利珠单抗可降低急性加重及挽救治疗风险。

局限性

  • 本文为预设分析,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Uncontrolled generalized myasthenia gravis (gMG) can lead to exacerbations that often warrant rescue therapy (RT) use, especially in moderate to severe cases. Inebilizumab, a monoclonal antibody that depletes cluster of differentiation 19+ B cells, demonstrated efficacy and safety in patients with gMG enrolled in the Myasthenia Gravis Inebilizumab Trial (MINT); the present analysis evaluated its effect on exacerbations and RT use. OBJECTIVE: To examine the effect of inebilizumab on exacerbations, including RT use, in participants enrolled in MINT. DESIGN, SETTING, AND PARTICIPANTS: MINT was a phase 3, international, randomized, placebo-controlled trial that enrolled participants between August 2020 and November 2023. The randomized controlled period was 52 weeks for the anti-acetylcholine receptor antibody positive (AChR+) subpopulation and 26 weeks for the anti-muscle-specific kinase antibody positive (MuSK+) subpopulation with an optional 3-year open-label extension. Participants were enrolled at 81 academic and nonacademic sites in 18 countries. MINT screened 485 patients with gMG (AChR+ or MuSK+) and enrolled adult participants with Myasthenia Gravis Activities of Daily Life (MG-ADL) scores of 6-10. This prespecified analysis was conducted between September 2024 and March 2025. INTERVENTIONS: Participants were randomized 1:1 to either inebilizumab or placebo and underwent a protocol-specified corticosteroid taper to 5 mg per day or less. MAIN OUTCOMES AND MEASURES: The frequency of exacerbations, defined as myasthenic crisis, worsening of individual MG-ADL scores, or RT use (intravenous immunoglobulin or plasma exchange). RESULTS: MINT enrolled 238 participants. The mean (SD) age at baseline was 47.5 (15.3) years, 144 (61%) were female, and the mean (SD) MG-ADL score was 9.1 (2.8). Inebilizumab reduced the risk of exacerbations compared with placebo in the combined population by week 26 (hazard ratio [HR], 0.41; 95% CI, 0.24-0.70), in the AChR+ subpopulation by week 52 (HR, 0.39; 95% CI, 0.23-0.68), and in the MuSK+ subpopulation by week 26 (HR, 0.21; 95% CI, 0.06-0.79). CONCLUSIONS AND RELEVANCE: In this prespecified analysis of a randomized clinical trial, inebilizumab treatment reduced exacerbation rate, including RT use, in participants with gMG who underwent a protocol-specified corticosteroid taper during MINT. These findings further support the clinical benefits of inebilizumab in AChR+ and MuSK+ gMG. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04524273.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Nowak RJ, Utsugisawa K, Benatar M, et al. Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42573995. doi:10.1001/jamaneurol.2026.2558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。